专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08912236B2 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye 有权
标题翻译：用于将受体酪氨酸激酶抑制（RTKi）化合物递送至眼睛的药物组合物
公开(公告)号：US08912236B2
公开(公告)日：2014-12-16
申请号：US12716624
申请日：2010-03-03
申请人： Bhagwati P. Kabra , Malay Ghosh , Adrian Sauceda
发明人： Bhagwati P. Kabra , Malay Ghosh , Adrian Sauceda
IPC分类号： A61K47/30 , A61K31/00 , A61K31/416 , A61K9/00 , A61K47/34
CPC分类号： A61K31/416 , A61K9/0051 , A61K47/34 , Y10S514/912
摘要： The present invention relates to development of efficacious pharmaceutical implant compositions comprising an active agent in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000.
摘要翻译：本发明涉及开发有效的药物植入物组合物，其包含治疗有效量的活性剂和分子量至少为2000的聚乙二醇。

2. 发明授权

US08469934B2 Pulsatile peri-corneal drug delivery device 有权
标题翻译：脉动型角膜周围药物输送装置
公开(公告)号：US08469934B2
公开(公告)日：2013-06-25
申请号：US13012885
申请日：2011-01-25
申请人： Alan L. Weiner , Bhagwati P. Kabra
发明人： Alan L. Weiner , Bhagwati P. Kabra
IPC分类号： A61F9/00 , A61K9/00 , A61K31/192 , A61K31/216 , A61K31/191 , A61P27/02
CPC分类号： A61F9/0026 , A61F9/0017 , A61K9/0009 , A61K9/0048 , A61N1/30
摘要： The present invention is directed to a pulsatile ophthalmic peri-corneal drug delivery device. The device includes an annular body and a mechanism for releasing multiple separate and distinct doses of a therapeutic composition over an extended period of time.
摘要翻译：本发明涉及脉动眼用角膜周围药物递送装置。该装置包括环形体和用于在延长的时间段内释放多个单独和不同剂量的治疗组合物的机构。

3. 发明申请

US20120245227A1 PHARMACEUTICAL COMPOSITIONS HAVING DESIRABLE BIOAVAILABILITY 有权
标题翻译：具有可靠生物利用度的药物组合物
公开(公告)号：US20120245227A1
公开(公告)日：2012-09-27
申请号：US13442475
申请日：2012-04-09
申请人： Bhagwati P. Kabra
发明人： Bhagwati P. Kabra
IPC分类号： A61K31/216 , A61P27/02
CPC分类号： A61K31/216 , A61K9/0048 , A61K31/215 , A61K31/535 , A61K31/542 , A61K31/5575 , A61K45/06 , A61K47/44 , Y02A50/465 , A61K2300/00
摘要： The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.
摘要翻译：本发明涉及提供药物组合物。组合物包括治疗剂和相对少量的表面活性剂以提供较高的治疗剂的生物利用度。作为其中治疗剂是前列腺素如曲伏前列素并且表面活性剂是植物油如蓖麻油的眼科组合物，该组合物是特别理想的。

4. 发明授权

US08268299B2 Self preserved aqueous pharmaceutical compositions 有权
标题翻译：自我保护的水性药物组合物
公开(公告)号：US08268299B2
公开(公告)日：2012-09-18
申请号：US11858781
申请日：2007-09-20
申请人： Bhagwati P. Kabra , Masood A. Chowhan , L. Wayne Schneider , Wesley Wehsin Han
发明人： Bhagwati P. Kabra , Masood A. Chowhan , L. Wayne Schneider , Wesley Wehsin Han
IPC分类号： A61K31/74 , A61K33/32 , A61K33/22 , A01N25/00 , A01N59/16 , A01N59/14
CPC分类号： A61K9/0048 , A61K47/02 , A61K47/10 , A61K47/26 , Y02A50/465 , Y02A50/473
摘要： The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borat or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred. Limiting the amount of divalent metals other than zinc and the amount of ionized salts present has also been determined to be important to maximize the antimicrobial activity of the balanced buffer systems.
摘要翻译：本发明涉及提供多剂量，自我保存的眼用组合物。组合物具有足够的抗微生物活性以满足USP防腐功效要求，以及类似的防腐标准品（例如EP和JP），而不需要存在常规的抗微生物防腐剂，例如苯扎氯铵。通过含有浓度为0.04至0.9mM，优选0.04至0.4mM的锌离子的平衡离子缓冲系统有效地保护了组合物。平衡缓冲系统的一个方面是存在的缓冲剂阴离子的量的限制为15mM或更低，优选5mM或更低的浓度。在优选的实施方案中，组合物还含有硼酸盐或最优选一种或多种硼酸盐/多元醇配合物。在这种络合物中使用丙二醇作为多元醇是非常优选的。限制锌以外的二价金属的量和存在的离子盐的量也被确定为使平衡缓冲体系的抗菌活性最大化是重要的。

5. 发明申请

US20120077769A1 TOPICAL OPHTHALMIC COMPOSITIONS CONTAINING TOBRAMYCIN AND DEXAMETHASONE 有权
标题翻译：含有羧甲基纤维素和DEXAMETHASONE的局部OPHALALMIC组合物
公开(公告)号：US20120077769A1
公开(公告)日：2012-03-29
申请号：US13311716
申请日：2011-12-06
申请人： Bhagwati P. Kabra
发明人： Bhagwati P. Kabra
IPC分类号： A61K31/704 , A61P27/02
CPC分类号： A61K47/36 , A61K9/0048 , A61K31/70 , A61K31/74 , Y10S514/912 , A61K2300/00
摘要： Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.
摘要翻译：描述含有妥布霉素，地塞米松和脱乙酰化黄原胶的眼药物组合物。组合物提供更长的眼睛保留量以增强妥布霉素和地塞米松的眼部生物利用度。在优选的实施方案中，组合物还提供地塞米松的改善的悬浮液。控制组合物中可离子化物质的浓度，以防止由于妥布霉素和黄原胶之间的离子相互作用而使黄原胶沉淀，同时允许在将组合物局部施用于眼睛时恢复粘度。公开了使用去乙酰化的黄原胶，以避免在储存期间由pH漂移引起的制剂不稳定性。

6. 发明申请

US20100324031A1 AQUEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING BORATE-POLYOL COMPLEXES 有权
标题翻译：含有硼酸酯 - 多元醇复合物的水性药物组合物
公开(公告)号：US20100324031A1
公开(公告)日：2010-12-23
申请号：US12817561
申请日：2010-06-17
申请人： Bhagwati P. Kabra
发明人： Bhagwati P. Kabra
IPC分类号： A61K31/542 , A61K31/498 , A61K47/24 , A61P27/02
CPC分类号： A61K47/02 , A61K9/0048 , A61K31/497 , A61K31/498 , A61K31/542 , A61K47/10 , A61K47/186 , A61K47/26 , A61K47/32 , A61K47/36 , A61K2300/00
摘要： The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate and a low concentration of benzalkonium chloride.
摘要翻译：本发明涉及提供多剂量眼用组合物。该组合物具有足够的抗微生物活性以满足USP防腐功效要求，以及类似的防腐标准（例如EP和JP）。组合物包括与两种不同的多元醇结合硼酸盐和低浓度的苯扎氯铵。

7. 发明申请

US20090234013A1 PHARMACEUTICAL COMPOSITIONS HAVING DESIRABLE BIOAVAILABILITY 有权
公开(公告)号：US20090234013A1
公开(公告)日：2009-09-17
申请号：US12403529
申请日：2009-03-13
申请人： Bhagwati P. Kabra
发明人： Bhagwati P. Kabra
IPC分类号： A61K31/192
CPC分类号： A61K31/216 , A61K9/0048 , A61K31/215 , A61K31/535 , A61K31/542 , A61K31/5575 , A61K45/06 , A61K47/44 , Y02A50/465 , A61K2300/00
摘要： The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.

8. 发明授权

US09707173B2 Pharmaceutical suspension 有权
公开(公告)号：US09707173B2
公开(公告)日：2017-07-18
申请号：US12630399
申请日：2009-12-03
申请人： Bhagwati P. Kabra
发明人： Bhagwati P. Kabra
IPC分类号： A61K31/14 , A61K31/496 , A61K31/542 , A61K9/00 , A61K9/10 , A61K47/10
CPC分类号： A61K9/0048 , A61K9/0043 , A61K9/0046 , A61K9/10 , A61K47/10
摘要： The present invention is directed to the provision of a pharmaceutical suspension. The suspension includes high molecular weight polyethylene glycol as a suspending agent. The suspension also typically includes an antimicrobial agent (e.g., polymeric quaternary ammonium compound), an antimicrobial system (e.g., borate/polyol complex system) or both. The suspension has been found particularly useful as an ophthalmic suspension, but can be used in other instances as well.

9. 发明授权

US09044484B2 Aqueous pharmaceutical compositions containing borate-polyol complexes 有权
标题翻译：含有硼酸盐 - 多元醇配合物的水性药物组合物
公开(公告)号：US09044484B2
公开(公告)日：2015-06-02
申请号：US12817561
申请日：2010-06-17
申请人： Bhagwati P. Kabra
发明人： Bhagwati P. Kabra
IPC分类号： A61K47/18 , A61K31/498 , A61P27/02 , A61K31/542 , A61K9/00 , A61K47/10 , A61K47/26 , A61K47/32
CPC分类号： A61K47/02 , A61K9/0048 , A61K31/497 , A61K31/498 , A61K31/542 , A61K47/10 , A61K47/186 , A61K47/26 , A61K47/32 , A61K47/36 , A61K2300/00
摘要： The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate and a low concentration of benzalkonium chloride.
摘要翻译：本发明涉及提供多剂量眼用组合物。该组合物具有足够的抗微生物活性以满足USP防腐功效要求，以及类似的防腐标准（例如EP和JP）。组合物包括与两种不同的多元醇结合硼酸盐和低浓度的苯扎氯铵。

10. 发明申请

US20120116216A1 Low Viscosity, Highly Flocculated Triamcinolone Acetonide Suspensions for Intravitreal Injection 有权
标题翻译：低粘度，高度絮凝的曲安奈德用于玻璃体内注射的丙酮酸悬浮液
公开(公告)号：US20120116216A1
公开(公告)日：2012-05-10
申请号：US13352009
申请日：2012-01-17
申请人： Bhagwati P. Kabra , Ruma Sarkar
发明人： Bhagwati P. Kabra , Ruma Sarkar
IPC分类号： A61B3/00 , A61P27/02 , A61K31/573
CPC分类号： A61K31/58 , A61K9/0048 , A61K9/10 , A61K47/34 , Y10S514/912 , Y10S514/913
摘要： Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-gauge needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.
摘要翻译：公开了曲安奈德悬浮液组合物。悬浮液组合物具有相对较低的粘度并且容易通过27或30号针挤出，但高度絮凝并容易再分散。组合物特别适用于玻璃体内注射。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式